--- title: "Nuvectis Pharma (NVCT.US) — Financial Reports" type: "Symbol" locale: "en" url: "https://longbridge.com/en/quote/NVCT.US/norm.md" symbol: "NVCT.US" name: "Nuvectis Pharma" parent: "https://longbridge.com/en/quote/NVCT.US.md" datetime: "2026-03-09T07:16:49.955Z" locales: - [en](https://longbridge.com/en/quote/NVCT.US/norm.md) - [zh-CN](https://longbridge.com/zh-CN/quote/NVCT.US/norm.md) - [zh-HK](https://longbridge.com/zh-HK/quote/NVCT.US/norm.md) --- > Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/NVCT.US/norm.md) | [繁體中文](https://longbridge.com/zh-HK/quote/NVCT.US/norm.md) # Nuvectis Pharma (NVCT.US) — Financial Reports ## Income Statement (USD) | Indicator | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | | --- | --- | --- | --- | --- | --- | | EPS | -0.3153 | -0.4354 | -0.2964 | -0.2674 | -0.3518 | | ROE | -137.92% | -193.55% | -133.96% | -139.09% | -241.42% | | Revenue | - | - | - | - | - | | Net income | -7.31M | -9.89M | -6.33M | -5.33M | -6.25M | | Operating income | -7.62M | -7.79M | -6.59M | -5.57M | -6.45M | | Gross margin | - | - | - | - | - | | Net margin | - | - | - | - | - | | Profit quality | - | - | - | - | - | ## Balance Sheet (USD) | Indicator | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | | --- | --- | --- | --- | --- | --- | | A&L | 31.71M | 35.59M | 27.01M | 30.15M | 18.61M | | Leverage | 1.72 | 1.48 | 1.60 | 1.44 | 1.92 | | BVPS | 0.7171 | 0.9364 | 0.7066 | 0.8866 | 0.4982 | | Turnover | - | - | - | - | - | | Cash & STI | 31.63M | 35.44M | 26.79M | 29.86M | 18.53M | | Inv & Rec | - | - | - | - | - | | LT assets | - | - | - | - | - | | Net debt | -31.63M | -35.44M | -26.79M | -29.86M | -18.53M | ## Cash Flow Statement (USD) | Indicator | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | | --- | --- | --- | --- | --- | --- | | Operating CF | -3.97M | -4.49M | -3.37M | -4.17M | -2.46M | | Investing CF | - | - | - | - | - | | Financing CF | 166000.00 | 13.14M | 296000.00 | 15.51M | 3.83M | | Free CF | -1.53M | -1.86M | -1.31M | -1.99M | -205625.00 | | OCF coverage | - | - | - | - | - | | Repaid & issued | - | - | - | - | - | | CapEx | - | - | - | - | - |